Future oncology (London, England)Apr 3, 2026

How GLP-1 receptor drugs and immune checkpoint inhibitors may interact: a review of their mechanisms and clinical effects

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Apr 4, 2026

Abstract

Real-world data indicate improved overall survival and fewer immune-related adverse events in patients with cancer receiving glucagon-like peptide-1 receptor agonists (GLP-1RAs) alongside immune checkpoint inhibitors (ICIs).

Obesity may enhance the effectiveness of immune checkpoint inhibitors despite its association with increased cancer risk.
Immunosuppressive mechanisms, such as regulatory T-cells and myeloid-derived suppressor cells, could limit long-term anti-tumor responses.
GLP-1RAs may serve as metabolic-immunologic adjuvants, potentially reprogramming the tumor microenvironment in obese patients undergoing ICI therapy.
Activation of specific signaling pathways by GLP-1R may suppress inflammation and improve T-cell function.
Concerns about the safety of GLP-1RAs, including risks of pancreatitis and diabetes, are not fully characterized.

Simplified

Obesity paradoxically increases sensitivity to immune checkpoint inhibitors (ICIs) despite elevating cancer risk, creating a clinical opportunity where metabolic dysfunction may generate a target-rich immune microenvironment. However, immunosuppressive mechanisms, including regulatory T-cells, myeloid-derived suppressor cells, and pro-inflammatory macrophages, can limit durable anti-tumor responses. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) extend beyond metabolic comorbidity management, functioning as metabolic-immunologic adjuvants capable of reprogramming the tumor microenvironment in obese patients receiving ICIs. A literature search was conducted in PubMed/MEDLINE through December 2025 using MeSH headings related to glucagon-like peptide-1 receptor agonists and immune checkpoint inhibitors. Mechanistically, GLP-1R signaling activates cAMP-PKA-AMPK pathways that suppress NF-κB-driven inflammation and promote macrophage repolarization, improving CD8 T-cell metabolic fitness, enhancing central memory formation, and reducing lipid-induced T-cell exhaustion. Real-world observational data across renal cell carcinoma, non-small cell lung cancer, colorectal cancer, and neuroendocrine neoplasms suggest improved overall survival, fewer immune-related adverse events, and lower cardiometabolic complications with concurrent GLP-1RA and ICI therapy. Pharmacovigilance concerns regarding pancreatitis, ICI-induced diabetes, and immune-related toxicities remain incompletely characterized. This review critically appraises mechanistic insights, real-world evidence, and safety considerations, proposing a translational-clinical research agenda to prospectively validate GLP-1RAs as rational adjuncts to checkpoint blockade.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.

PubMed

How GLP-1 receptor drugs and immune checkpoint inhibitors may interact: a review of their mechanisms and clinical effects

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief